With two Phase III trials under way testing its treatment to prevent vein-graft failure after surgery, Corgentech Inc. is joining with Bristol-Myers Squibb Co. in a deal that's expected to get revenue flowing better. (BioWorld Today)

Money might not buy love but, as Pfizer Inc.'s blockbuster Viagra proved, it can do wonders for sexual capability in men who have the wherewithal to pay for the magic blue pill. Talk about "hard cash." (BioWorld Financial Watch)

With an ultrasound imaging agent in Phase III, Acusphere Inc. became the first kernel of corn to pop in the IPO pan, raising $52.5 million by pricing its 3.75 million shares at $14 - the mid-point of its targeted $13 to $15 range. (BioWorld Today)